|
Lecturer
City St George’s, University of London (SGUL), United Kingdom (UK)
Email: mpaul@citystgeorges.ac.uk
VALIDATE Role:
Network Associate
Research Keywords:
TB, Plant Biotechnology, Buruli Ulcer
Biography:
I am an immunologist with a keen interest in the plant platform for the production of therapeutically relevant proteins, including vaccines and antibodies. The plant platform offers advantages over other approaches for recombinant protein manufacture which may offer an attractive route for development.
I am also interested in the mucosal response to infection with TB, COVID-19 and RSV.
Key Publications:
- Paul, M. J., Hudda, M. T., Pallett, S., Groppelli, E., Boariu, E., Finardi, N. F., . . . Ma, J. K. -C. (2025). Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination. Vaccine, 56, 127175. doi:10.1016/j.vaccine.2025.127175
- Paul, M. J., Thangaraj, H., & Ma, J. K. (2015). Commercialization of new biotechnology: a systematic review of 16 commercial case studies in a novel manufacturing sector. Plant Biotechnology Journal, 13(8), 1209-1220. doi:10.1111/pbi.12426
- Paul, M., Reljic, R., Klein, K., Drake, P. M. W., van Dolleweerd, C., Pabst, M., . . . Ma, J. K. -C. (2014). Characterization of a plant-produced recombinant human secretory IgA with broad neutralizing activity against HIV. mAbs, 6(6), 1585-1597. doi:10.4161/mabs.36336
|
